34 results about "Luteal phase" patented technology

The present invention relates to the use of an oxytocin receptor antagonist in females undergoing embryo transfer as part of an assisted reproductive technology. In particular, methods are provided for increasing ongoing implantation rate, increasing ongoing pregnancy rate, increasing clinical pregnancy rate, and / or increasing live birth rate in a female subject undergoing embryo transfer. Specifically, the antagonists are released in the luteal phase when the endometrium is receptive for embryo implantation and / or when the embryo has reached the blastocyst-stage.

A method of treating infertility disorders by 1) administering an LH-RH antagonist, preferably Cetrorelix, in amounts to selectively suppress endogenous LH but not FSH secretion and 2) inducing follicle growth by administration of exogenous gonadotropin. The selective suppression OF LH allows FSH secretion to be at natural levelS thereby not affecting individual estrogen development. The LH-RH antagonist can be given as a single or dual subcutaneous dose in the range of 1 mg to 10 mg, preferably 2 mg-6 mg. In multiple dosing-posology, LH-RH antagonist can be administered subcutaneously in an amount in the range of 0.1 to 0.5 mg of LH-RH antagonist / day. LH-RH antagonist is applied starting cycle day 1 to 10, preferably on day 4 to 8, and ovulation can be induced between day 9 and 20 of the menstruation cycle by administering rec. LH, native LH-RH, LH-RH agonist or by HCG. In addition rec. LH, native LH-RH or LH-RH agonist can be given to avoid hyperstimulation syndrome and native LH-RH or a LH-RH agonist can be administered to avoid luteal phase stimulation by neutralizing the negative effects of HCG.

The present invention relates to methods of inducing ovulation in a female host comprising the administration of a non-polypeptide cyclic adenosine monophosphate (cAMP) level modulator to the female host. In another aspect, the invention provides for specific administration of the phosphodiesterase inhibitor prior to the luteal phase of the host's ovulatory cycle. Preferred non-polypeptide cAMP level modulators include phosphodiesterase inhibitors, particularly inhibitors of phosphodiesterase 4 isoforms.

The invention discloses a traditional Chinese medicine composition for treating luteal phase defect type infertility and menstrual disorder. The traditional Chinese medicine composition disclosed by the invention is prepared from the following components in parts by weight: 1-6 parts of fried radix paeoniae alba, 1-9 parts of common yam rhizome, 1-6 parts of dogwood, 0.5-3 parts of vinegar baked bupleurum root, 1-9 parts of the seed of Chinese dodder, 1.5-9 parts of sliced cornu cervi, 1.5-9 parts of amethyst and 1-6 parts of radix salviae miltiorrhizae. According to the compound composition provided by the invention, by means of syndrome differentiation and treatment, the formula is obtained through a lot of experimental screening under the guidance of theories of traditional Chinese medicines; experimental results show that the traditional Chinese medicine composition is capable of improving the structure and form of ovary mitochondria endoplasmic reticulum, improving structures of endometrial glands and mesenchyme, adjusting ovary secreted active substances E2 and P, reducing endometrium estrogen receptors and progestrone receptors and increasing expression of integrins alpha v and beta 3; therefore, the endometrium receptivity can be increased; the embryo implantation action is promoted; the traditional Chinese medicine composition has the good effect for treating infertility; and furthermore, the traditional Chinese medicine composition is free from toxic and side effect, and safe and reliable to use.